NASDAQ$AXGN

Axogen Inc. · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Axogen's financial performance remained stable with a slight revenue increase excluding Avive sales, while adjusted net loss and EBITDA loss widened compared to the previous year.

Axogen, Inc. reported first quarter 2022 financial results with net revenue of $31.0 million, matching the first quarter of 2021. Excluding Avive revenue from the previous year, revenue increased by 6%. The company's adjusted net loss was $8.5 million, or $0.20 per share, and the adjusted EBITDA loss was $7.4 million.

  • Net revenue matched the first quarter of 2021 at $31.0 million.
  • Excluding Avive revenue from Q1 2021, revenue increased by 6%.
  • Adjusted net loss was $8.5 million, or $0.20 per share.
  • RECON study achieved its primary endpoint, a critical milestone for Avance Nerve Graft.

Headline financials

Total Revenue

$31M

Previous: $31M-0.1%
EPS (adj)

-$0.20

Previous: -$0.08-150.0%
Gross Margin

82.1%

No prior period
Capital Expenditures

-$5.04M

Previous: -$3.1M-62.7%
Free Cash Flow

-$16.5M

Previous: -$9.76M-69.3%
Net Income

-$11.5M

Previous: -$6.66M-72.3%
Operating Income

-$11.3M

Previous: -$6.22M-82.0%
Gross Profit

$25.5M

Previous: $25.9M-1.6%
Cash & Equivalents

$14.6M

Previous: $39.8M-63.5%
Total Assets

$198M

Previous: $197M+0.3%
Stock-Based Comp

$2.68M

Previous: $2.69M-0.6%

Revenue & EPS history

Axogen · Revenue · Quarterly

$31M

Q1 2022-0.1%vs Q1 2021
Beat estimate in 7 of 16 quarters(44%)
ActualEstimate

Forward guidance

The Company continues to expect 2022 revenue will be in the range of $135.0 million to $142.0 million. Full-year 2022 gross margin is expected to be above 80%.

Tailwinds

  • 2022 revenue will be in the range of $135.0 million to $142.0 million.
  • Represents approximately 10% to 15% growth over 2021 revenue excluding the impact of $4.1 million of Avive revenue in 2021.
  • Full-year 2022 gross margin is expected to be above 80%.
  • Procedure trends improved during the quarter.
  • Continued growth is expected as surgeons adopt the Axogen nerve repair algorithm.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

+1.4%

Avg return

Earnings day

+2.4%

Avg return

5 days after

+6.1%

Avg return

30 days after

52%

33 / 64 earnings

Positive

+39.1%

Q2 2024

Best reaction

-27.3%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+6.6%+9.9%+2.6%
Q4 2025-6.6%-10.3%-8.8%
Q3 2025+22.8%+28.6%+58.5%
Q1 2025-23.2%-33.6%-33.4%
Q4 2024+11.7%+11.1%+5.4%
Q3 2024-17.4%-13.4%-2.7%
Q2 2024+39.1%+42.2%+64.4%
Q1 2024-11.7%-11.1%+4.1%
Q4 2023-14.4%-17.4%-26.7%
Q3 2023+37.4%+27.7%+88.8%
Q2 2023-20.8%-27.9%-27.0%
Q1 2023-1.8%-4.6%-0.8%
Q4 2022+11.6%+9.2%+37.8%
Q3 2022+19.0%+21.4%+0.6%
Q2 2022+2.1%+1.2%-10.7%
Q1 2022+23.4%+17.7%+16.8%
Q4 2021+8.0%+27.1%+6.2%
Q3 2021-13.3%-6.0%-37.3%
Q2 2021-2.5%-9.5%-12.5%
Q1 2021+14.9%+13.3%-1.2%
Q4 2020+3.6%+7.0%-7.7%
Q3 2020+3.4%+10.4%+18.0%
Q2 2020+0.3%-2.3%-1.7%
Q1 2020-14.7%-9.6%+10.9%
Q4 2019-17.6%-15.8%-36.3%
Q3 2019+12.4%+13.3%+23.8%
Q2 2019-27.3%-21.8%-5.5%
Q1 2019-2.1%-5.4%-15.7%
Q4 2018+1.6%+6.7%+13.4%
Q3 2018+9.3%+12.8%-1.3%
Q2 2018-12.6%-13.1%-2.4%
Q1 2018-5.1%+5.2%+14.2%
Q4 2017+8.8%+4.5%+17.0%
Q3 2017+10.7%+15.3%+28.5%
Q2 2017-4.8%-6.4%+14.7%
Q1 2017+3.3%+3.7%+25.6%
Q4 2016-0.5%-0.5%-5.2%
Q3 2016-1.7%-10.9%-7.4%
Q2 2016+25.1%+26.2%+32.9%
Q1 2016-0.4%
Q4 2015-4.7%
Q3 2015+17.3%
Q2 2015+5.4%
Q1 2015+3.1%
Q4 2014+3.8%
Q3 2014+5.5%
Q2 2014+1.3%
Q1 2014+1.6%
Q4 2013-8.5%
Q3 2013+1.8%
Q2 2013-0.3%
Q1 2013-14.7%
Q4 2012+4.5%
Q3 2012-1.8%
Q2 2012+18.2%
Q1 2012+0.3%
Q4 2011-4.5%
Q3 2011-14.8%
Q2 2010+0.0%
Q2 2011+0.0%
Q1 2011+0.0%
Q4 2010-6.8%
Q3 2010+9.7%
Q1 2010-0.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro